Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.56 |
| ▸ | MME | P08473 | 6/20 | 0.53 |
| ▸ | CA2 | P00918 | 5/20 | 0.41 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.39 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.37 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | THPO | P40225 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4812263 | 1.00 | TGFBR1 (0.56) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL1995530 | 1.00 | TGFBR1 (0.56) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL4812250 | 0.83 | TGFBR1 (0.54) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL6315187 | 0.83 | TGFBR1 (0.54) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL16314008 | 0.81 | TGFBR1 (0.52) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL7753529 | 0.81 | MME (0.42) | TGFBR1MMECA2CA4FOLH1 | |
| SCHEMBL11303240 | 0.81 | TGFBR1 (0.52) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL4193694 | 0.81 | MME (0.55) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL783083 | 0.81 | TGFBR1 (0.57) | TGFBR1MMECA2CA1FNTA | |
| SCHEMBL783082 | 0.81 | TGFBR1 (0.57) | TGFBR1MMECA2CA1FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110982796-B | AMA synthetase and application thereof in synthesizing AMA or derivatives thereof | 北京大学 | 2021-11-09 | — | — | CN | claimed |
| CN-110982796-A | AMA synthetase and application thereof in synthesizing AMA or derivatives thereof | 北京大学 | 2020-04-10 | — | — | CN | claimed |
| EP-1628621-A2 | POLYMERIC CONJUGATES FOR TISSUE ACTIVATED DRUG DELIVERY | Vectramed, Inc. (US) | 2006-03-01 | — | — | EP | claimed |
| WO-2004110358-A2 | POLYMERIC CONJUGATES FOR TISSUE ACTIVATED DRUG DELIVERY | VECTRAMED, INC. (US) | 2004-12-23 | — | — | WO | claimed |
| US-20040228831-A1 | Polymeric conjugates for tissue activated drug delivery | VECTRAMED, INC. | 2004-11-18 | — | — | US | claimed |
| JP-2002542304-A | — | — | 2002-12-10 | — | — | JP | claimed |
| EP-1176985-A2 | ENZYMATICALLY ACTIVATED POLYMERIC DRUG CONJUGATES | Vectramed, Inc. (US) | 2002-02-06 | — | — | EP | claimed |
| WO-2000064486-A2 | ENZYMATICALLY ACTIVATED POLYMERIC DRUG CONJUGATES | VECTRAMED, INC. (US) | 2000-11-02 | — | — | WO | claimed |
| WO-1996032372-A1 | SERINE DERIVATIVES AND USE THEREOF IN COSMETICS | SOCHINAZ S.A. (FR) | 1996-10-17 | — | — | WO | claimed |
| US-11992518-B2 | Molecular vaccines for infectious disease | AGILENT TECHNOLOGIES, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| CN-110982796-B | AMA synthetase and application thereof in synthesizing AMA or derivatives thereof | 北京大学 | 2021-11-09 | — | — | CN | disclosed |
| US-10968269-B1 | MHC multimers in borrelia diagnostics and disease | AGILENT TECHNOLOGIES, INC. (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210047383-A1 | MHC Multimers in Borrelia Diagnostics and Disease | DAKO DENMARK APS (DK) | 2021-02-18 | — | — | US | disclosed |
| US-20200347103-A1 | MHC MULTIMERS IN TUBERCULOSIS DIAGNOSTICS, VACCINE AND THERAPEUTICS | AGILENT TECHNOLOGIES INC (US) | 2020-11-05 | — | — | US | disclosed |
| EP-0926955-A1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | Merck & Co., Inc. (US) | 1999-07-07 | — | — | EP | disclosed |
| EP-0871650-A2 | SOLID PHASE ORGANIC SYNTHESIS | Genzyme Limited (GB) | 1998-10-21 | — | — | EP | disclosed |
| WO-1998010651-A1 | CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER | MERCK & CO., INC. (US) | 1998-03-19 | — | — | WO | disclosed |
| WO-1997020855-A2 | SOLID PHASE ORGANIC SYNTHESIS | GENZYME LIMITED (GB) | 1997-06-12 | — | — | WO | disclosed |
| WO-1996032372-A1 | SERINE DERIVATIVES AND USE THEREOF IN COSMETICS | SOCHINAZ S.A. (FR) | 1996-10-17 | — | — | WO | disclosed |
| US-5091367-A | Fertility agents, antifertility agents, hormone inhibitors | HOECHST AKTIENGESELLSCHAFT (DE) | 1992-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040228831-A1 | Polymeric conjugates for tissue activated drug delivery | SI, CD44, MMP1 | TGFBR1 2834/4885MME 383/4885CA2 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.